了解患者层面因素与参与乳腺癌临床试验之间的关联
Nicole E Caston1,2, Luqin Deng3, Courtney P Williams3
1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA.
积极的态度和对临床试验的更多知识与更高的乳腺癌 (BC) 患者参与有关. 促进积极态度和教育的干预措施可以增加试验招生和多样性.
科学领域:
- 癌症学
- 临床试验
- 健康上的差异
背景情况:
- 乳腺癌 (BC) 临床试验对于新疗法至关重要,但往往缺乏多样化的患者代表.
- 患者的社会人口结构,态度和知识可能会影响参与BC临床试验.
研究的目的:
- 评估患者社会人口结构,态度,知识和参与乳腺癌临床试验之间的关联.
- 确定可能改善临床试验多样性和入学率的因素.
主要方法:
- 由TBCRC和PAF收集的612名患有BC诊断的妇女的调查数据的横截面分析.
- 评估BC临床试验参与,态度 (对癌症试验态度量表),知识和社会人口统计.
- 使用描述性,双变量分析 (克拉默的V,科恩的d) 和结构方程建模 (SEM) 来估计标准化总效应 (bTot).
主要成果:
- 18% 的受访者表示参与试验.
- 对试验的积极态度与参与率显著相关 (科恩的d=0.48).
- 态度和知识与两组试验参与有积极的关联 (bTot范围为0.13至0.22),而知识与态度有关 (bTot范围为0.15至0.27).
结论:
- 积极的态度和更高的知识与参与乳腺癌临床试验有关.
- 促进积极态度和增加试验教育的干预措施可能会提高招生率和多样性.
- 需要进一步的研究来证实试验对参与者的直接因果关系.
更多相关视频
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Clinical Trials
There are four phases in a clinical trial. A phase one...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Clinical Trials: Overview
Cancer Survival Analysis
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
